Literature DB >> 19701227

Dialysis: the sweetness of glitazones: randomized trials needed.

Carmine Zoccali.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19701227     DOI： 10.1038/nrneph.2009.127

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

Review 1.  Invited commentary: propensity scores.

Authors:  M M Joffe; P R Rosenbaum
Journal:  Am J Epidemiol       Date:  1999-08-15       Impact factor: 4.897

2.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

3.  HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients.

Authors:  Nancy A Mason; George R Bailie; Sudtida Satayathum; Jennifer L Bragg-Gresham; Takashi Akiba; Tadao Akizawa; Christian Combe; Hugh C Rayner; Akira Saito; Brenda W Gillespie; Eric W Young
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

4.  Rosiglitazone is associated with mortality in chronic hemodialysis patients.

Authors:  Sylvia P B Ramirez; Justin M Albert; Margaret J Blayney; Francesca Tentori; David A Goodkin; Robert A Wolfe; Eric W Young; George R Bailie; Ronald L Pisoni; Friedrich K Port
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

5.  Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial.

Authors:  Johanna C Korevaar; G W Feith; Friedo W Dekker; Jeannette G van Manen; Elisabeth W Boeschoten; Patrick M M Bossuyt; Raymond T Krediet
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

6.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

7.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Authors:  Bengt C Fellström; Alan G Jardine; Roland E Schmieder; Hallvard Holdaas; Kym Bannister; Jaap Beutler; Dong-Wan Chae; Alejandro Chevaile; Stuart M Cobbe; Carola Grönhagen-Riska; José J De Lima; Robert Lins; Gert Mayer; Alan W McMahon; Hans-Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; Sandor Sonkodi; D Sci; Gultekin Süleymanlar; Dimitrios Tsakiris; Vladimir Tesar; Vasil Todorov; Andrzej Wiecek; Rudolf P Wüthrich; Mattis Gottlow; Eva Johnsson; Faiez Zannad
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

8.  Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.

Authors:  Christian A Schneider; Ele Ferrannini; Ralph Defronzo; Guntram Schernthaner; John Yates; Erland Erdmann
Journal:  J Am Soc Nephrol       Date:  2007-12-05       Impact factor: 10.121

9.  Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes.

Authors:  Steven M Brunelli; Ravi Thadhani; T Alp Ikizler; Harold I Feldman
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

10.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

Authors:  A Michael Lincoff; Kathy Wolski; Stephen J Nicholls; Steven E Nissen
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.